CA3128857A1 - Methods and compositions for treating cancer - Google Patents

Methods and compositions for treating cancer Download PDF

Info

Publication number
CA3128857A1
CA3128857A1 CA3128857A CA3128857A CA3128857A1 CA 3128857 A1 CA3128857 A1 CA 3128857A1 CA 3128857 A CA3128857 A CA 3128857A CA 3128857 A CA3128857 A CA 3128857A CA 3128857 A1 CA3128857 A1 CA 3128857A1
Authority
CA
Canada
Prior art keywords
compound
pla2
gib
cancer
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3128857A
Other languages
English (en)
French (fr)
Inventor
Jacques Theze
Blanche TAMARIT
Philippe Pouletty
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Diaccurate SA
Original Assignee
Diaccurate SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diaccurate SA filed Critical Diaccurate SA
Publication of CA3128857A1 publication Critical patent/CA3128857A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01004—Phospholipase A2 (3.1.1.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3128857A 2019-02-06 2020-02-05 Methods and compositions for treating cancer Pending CA3128857A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19305140.6 2019-02-06
EP19305140.6A EP3693063A1 (en) 2019-02-06 2019-02-06 Methods and compositions for treating cancer
PCT/EP2020/052818 WO2020161165A1 (en) 2019-02-06 2020-02-05 Methods and compositions for treating cancer

Publications (1)

Publication Number Publication Date
CA3128857A1 true CA3128857A1 (en) 2020-08-13

Family

ID=65635594

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3128857A Pending CA3128857A1 (en) 2019-02-06 2020-02-05 Methods and compositions for treating cancer

Country Status (9)

Country Link
US (1) US20220127377A1 (ko)
EP (2) EP3693063A1 (ko)
JP (1) JP2022519716A (ko)
KR (1) KR20220143552A (ko)
CN (1) CN113710321A (ko)
CA (1) CA3128857A1 (ko)
IL (1) IL285036A (ko)
MX (1) MX2021009195A (ko)
WO (1) WO2020161165A1 (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024106586A1 (ko) * 2022-11-18 2024-05-23 (주)케어젠 발모 촉진 및 탈모 억제 활성을 갖는 펩타이드 및 이의 용도

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
USRE32011E (en) 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4902614A (en) 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
JPS63501765A (ja) 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0768377A1 (en) 1988-09-02 1997-04-16 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2109602C (en) 1990-07-10 2002-10-01 Gregory P. Winter Methods for producing members of specific binding pairs
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
DK1279731T3 (da) 1991-03-01 2007-09-24 Dyax Corp Fremgangsmåde til udvikling af bindende miniproteiner
CA2108147C (en) 1991-04-10 2009-01-06 Angray Kang Heterodimeric receptor libraries using phagemids
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
AUPP182398A0 (en) * 1998-02-13 1998-03-12 Garvan Institute Of Medical Research Cyclic peptide inhibitors of pla2
AU2001272915A1 (en) * 2000-07-14 2002-01-30 Eli Lilly And Company Method for treating sepsis
AUPS282602A0 (en) * 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
NZ580115A (en) 2004-09-23 2010-10-29 Genentech Inc Cysteine engineered antibody light chains and conjugates
EP2960252A1 (en) 2014-06-26 2015-12-30 Institut Pasteur Phospholipase for treatment of immunosuppression
CN107206088A (zh) * 2014-12-05 2017-09-26 豪夫迈·罗氏有限公司 使用pd‑1轴拮抗剂和hpk1拮抗剂用于治疗癌症的方法和组合物
JP2018526440A (ja) 2015-08-31 2018-09-13 ディアキュレートＤｉａｃｃｕｒａｔｅ 免疫系を刺激するためのインドール化合物の使用
CN108472329B (zh) 2015-10-09 2022-04-05 迪亚库雷特公司 多肽刺激免疫系统的用途
WO2017074774A1 (en) * 2015-10-28 2017-05-04 Yale University Humanized anti-dkk2 antibody and uses thereof
CN112972492A (zh) * 2015-12-16 2021-06-18 沃尔特及伊莱萨霍尔医学研究院 Nk细胞中对细胞因子诱导的sh2蛋白的抑制
EP3530282A1 (en) * 2018-02-27 2019-08-28 Diaccurate Therapeutic methods
EP3533460A1 (en) * 2018-03-02 2019-09-04 Diaccurate Therapeutic anti-spla2-gib antibodies and the uses thereof

Also Published As

Publication number Publication date
JP2022519716A (ja) 2022-03-24
EP3921036A1 (en) 2021-12-15
IL285036A (en) 2021-09-30
KR20220143552A (ko) 2022-10-25
CN113710321A (zh) 2021-11-26
MX2021009195A (es) 2021-09-08
WO2020161165A1 (en) 2020-08-13
EP3693063A1 (en) 2020-08-12
US20220127377A1 (en) 2022-04-28

Similar Documents

Publication Publication Date Title
US20230110249A1 (en) Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
CN110536903B (zh) 抗ox40抗体及其用途
JP6654165B2 (ja) 抗ｔｉｅ２抗体およびその使用
JP5814790B2 (ja) デングウイルス中和抗体およびその使用
TWI832808B (zh) 中和抗tl1a之單株抗體
CN106794246B (zh) 肿瘤抗原特异性抗体和tlr3刺激以增强检查点干扰癌症疗法的性能
KR102662915B1 (ko) 항-b7-h3 항체
WO2019042285A1 (zh) 抗cd47抗体及其用途
JP2009515827A (ja) 治療薬
JP2006519163A (ja) 癌転移および癌転移に伴なう骨量減少を防止および処置するための方法
JP2022547850A (ja) 抗ｔｉｇｉｔ免疫阻害剤及び応用
US20230174664A1 (en) Antibodies to carbohydrate antigens
JP2022523710A (ja) Ｃｄ４４に特異的な抗体
JP2022514693A (ja) Ｍｕｃ１８に特異的な抗体
RU2654584C2 (ru) Новые антитела к фосфорилхолину
TW202306993A (zh) Ｔｒｅｍ２之促效劑
NZ714716A (en) Method for preparing deep-frozen vegetables pieces
JP2022514786A (ja) Ｍｕｃ１８に特異的な抗体
US20220127377A1 (en) Methods and compositions for treating cancer
KR102231685B1 (ko) 인간 항-il-32 항체
CN116323657A (zh) 同时靶向PD-L1和TGFβ的双功能分子及其医药用途
CA2585156A1 (en) Duffy antigen receptor for chemokines and use thereof
JP2024514855A (ja) Ｄｌｌ３に対する結合分子及びその使用
WO2017211313A1 (zh) 长效pcsk9特异性的结合蛋白及其应用
EP4293047A1 (en) Anti-pd-l1 antibody and use thereof